| Outcome Measures: |
Primary: Number of Participants Experiencing an Adverse Event (AE), Up to Day 10 of each dosing period|Number of Participants Discontinuing Study Drug Due to an AE, Up to Day 8 of each dosing period|Change from baseline in 24-hour urinary glucose excretion, Baseline and 24 hours|Area under the plasma concentration-time curve (AUC) from Time 0 to infinity (AUCinf) for ertugliflozin, Up to Day 4 of each treatment period|Area under the plasma concentration-time curve (AUC) from Time 0 to time of the last quantifiable concentration (AUClast) for ertugliflozin, Up to Day 4 of each treatment period|Maximum plasma concentration (Cmax) of ertugliflozin, Up to Day 4 of each treatment period|Time taken to reach the maximum observed plasma concentration (Tmax) of ertugliflozin, Up to Day 4 of each treatment period|Ertugliflozin half life (t1/2), Up to Day 4 of each treatment period|Apparent clearance (CL/F) after a single dose of ertugliflozin, Up to Day 4 of each treatment period|Apparent volume of distribution (Vz/F), Up to Day 4 of each treatment period | Secondary: Urinary glucose excretion over 72 hours, Up to 72 hours of each dosing period|Change from baseline in 24-hour weighted mean glucose, Baseline and 24 hours|Inhibition of glucose reabsorption, Up to 24 hours of each dosing period|Renal clearance (CLr) of Ertugliflozin, Up to 24 hours of each dosing period|Urinary recovery of Ertugliflozin, Up to 24 hours of each dosing period
|
